

Summary of Consolidated Financial Results for the Three Months Ended June 30, 2020 (Based on Japanese GAAP)

August 3, 2020

Company name: ASKA Pharmaceutical Co., Ltd
 Stock exchange listing: Tokyo
 Stock code: 4514 URL <http://www.aska-pharma.co.jp/english/>
 Representative : President and Representative Director Takashi Yamaguchi
 Inquiries : General Manager Corporate Planning Department Tomohito Nagao TEL +81-3-5484-8366
 Scheduled date to file Securities Report : August 7, 2020
 Scheduled date to commence dividend payments : -
 Preparation of supplementary material on financial results : No
 Holding of financial results meeting : No

(Amounts less than one million yen are rounded down)

1. Consolidated Financial Results for the Three Months Ended June 30, 2020 (from April 1, 2020 to June 30, 2020)

(1) Consolidated Operating Results (Cumulative)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended June 30, 2020	13,714	△2.0	898	7.2	987	1.8	739	31.1
Three months ended June 30, 2019	13,991	9.6	837	△31.2	969	△28.4	563	△46.9

	Earnings per share	Diluted earnings per share
	Yen	Yen
Three months ended June 30, 2020	26.09	—
Three months ended June 30, 2019	19.96	—

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
	Millions of yen	Millions of yen	%
As of June 30, 2020	80,166	42,273	52.7
As of March 31, 2020	80,239	41,573	51.8

2. Cash Dividends

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2020	—	7.00	—	10.00	17.00
Year ended March 31, 2021 (Forecast)		7.00	—	7.00	14.00

3. Forecast of Consolidated Financial Results for the Year Ending March 31, 2021 (from April 1, 2020 to March 31, 2021)

percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	53,000	0.9	2,000	32.7	1,900	10.8	1,500	131.1	52.95

※ Notes

(1) Changes in significant subsidiaries during the three months ended June 30, 2020
(changes in specified subsidiaries resulting in the change in scope of consolidation): No

(2) Application of special accounting methods for preparing quarterly consolidated financial statements: No

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements

Changes in accounting policies due to revisions to accounting standards and other regulations: No

Changes in accounting policies due to other reasons: No

Changes in accounting estimates: No

Restatement of prior period financial statements: No

(4) Number of issued shares (common shares)

1) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2020	30,563,199	As of March, 2020	30,563,199
---------------------	------------	-------------------	------------

2) Number of treasury shares at the end of the period

As of June 30, 2020	2,219,679	As of March, 2020	2,234,979
---------------------	-----------	-------------------	-----------

3) Average number of shares during the period (cumulative from the beginning of the fiscal year)

As of June 30, 2020	28,334,145	As of June 30, 2019	28,246,117
---------------------	------------	---------------------	------------

Quarterly Consolidated Financial Statements
(1) Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2020	As of June 30, 2020
Assets		
Current assets		
Cash and deposits	7,294	5,643
Notes and accounts receivable	13,792	16,166
Merchandise and finished goods	9,087	8,992
Work in process	353	469
Raw materials and supplies	4,602	4,468
Other	2,196	2,211
Allowance for doubtful accounts	△0	△0
Total current assets	37,326	37,952
Non-current assets		
Property, plant and equipment	13,539	13,328
Intangible assets		
Intangible assets in progress	8,446	8,421
Other	5,137	4,648
Total intangible assets	13,584	13,070
Investments and other assets		
Investments securities	9,794	10,118
Other	6,012	5,713
Allowance for doubtful accounts	△17	△17
Total investments and other assets	15,789	15,814
Total non-current assets	42,913	42,213
Total assets	80,239	80,166
Liabilities		
Current liabilities		
Notes and accounts payable –trade	3,239	3,245
Electronically recorded monetary claims	2,801	2,701
Short(Long)-term loans payable	2,748	4,448
Other provision	997	483
Other	7,340	6,347
Total current liabilities	17,127	17,226
Non-current liabilities		
Long-term loans payable	13,671	12,796
Provision for environmental measures	820	820
Retirement benefit liabilities	6,655	6,666
Other	390	382
Total non-current liabilities	21,537	20,666
Total liabilities	38,665	37,892
Net assets		
Shareholders' equity		
Share capital	1,197	1,197
Capital surplus	928	928
Retained earnings	39,560	40,015
Treasury shares	△2,191	△2,174
Total shareholders' equity	39,495	39,967
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2,293	2,536
Foreign currency translation adjustment	△9	△34
Remeasurements of defined benefit plans	△205	△195
Total accumulated other comprehensive income	2,078	2,306
Total net assets	41,573	42,273
Total liabilities and net assets	80,239	80,166

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)

(Millions of yen)

	Three months ended June 30, 2019	Three months ended June 30, 2020
Net sales	13,991	13,714
Cost of sales	7,361	7,640
Gross profit	6,629	6,073
Selling, general and administrative expenses	5,791	5,175
Operating profit	837	898
Non-operating income		
Interest income	0	0
Dividend income	120	125
Other	60	45
Total non-operating income	180	171
Non-operating expenses		
Interest expenses	13	14
Real estate rent	27	28
Other	6	38
Total non-operating expenses	48	81
Ordinary profit	969	987
Extraordinary income		
Capital gains on insurance agency business	49	—
Total extraordinary income	49	—
Extraordinary losses		
Loss on devaluation of investment securities	110	—
Total extraordinary losses	110	—
Profit before income taxes	907	987
Income taxes – current	35	151
Income taxes – deferred	308	96
Total income taxes	344	248
Profit	563	739
Profit attributable to owners of parent	563	739

(Consolidated Statements of Income)

(Millions of yen)

	Three months ended June 30, 2019	Three months ended June 30, 2020
Profit	563	739
Other comprehensive income		
Valuation difference on available-for-sale securities	△302	243
Remeasurements of defined benefit plans, net of tax	10	10
Share of other comprehensive income of associates accounted for using equity method	5	△25
Total other comprehensive income	△286	227
Comprehensive income	277	966
Details		
Comprehensive income attributable to owners of parent	277	966

Supplemental Material

(1)Sales of Main Products

S a l e s o f M a i n P r o d u c t s
(F Y 2 0 2 1 F i r s t Q u a r t e r A c t u a l)

(Billions of yen)

Therapeutic category	Products	FY2020		FY2021		QOQ(%)
		Q1 Actual	FY2020 Actual	Q1 Actual	FY2021 Forecast	
Antihypertensive agent	CANDESARTAN*	3.76	13.22	3.24	11.49	△ 14.0
Thyroid hormone	THYRADIN	1.79	6.89	1.85	7.17	3.0
LH-RH derivative	LEUPRORELIN	1.29	4.79	1.15	3.64	△ 10.8
GnRH antagonist	RELUMINA	0.31	2.62	1.13	5.92	268.9
Poorly absorbable rifamycin antimicrobial agent	RIFXIMA	0.91	3.78	1.12	4.83	22.4
Dysmenorrhea agent	FREWELL	0.48	2.25	0.65	2.47	35.9
Antithyroid agent	MERCAZOLE	0.36	1.38	0.36	1.38	△ 0.5
Hyperlipidemic agent	LIPDIL	0.40	1.37	0.35	1.19	△ 13.2
Antihypertensive agent	AMLODIPINE	0.44	1.44	0.34	1.18	△ 22.7
Amyotrophic lateral sclerosis agent	RILUZOLE	0.19	0.85	0.29	0.96	53.4
Prostatecancer therapeutic agent	BICALUTAMIDE	0.39	1.26	0.28	1.06	△ 29.0
Tocolytic agent Inhibitory and therapeutic agent for the onset of eclampsia	MAGSENT	-	0.06	0.24	0.88	-

*Including compounding agents